According to a new report by Polaris Market Research, the global prostate cancer treatment market was valued at USD 15.17 billion in 2025 and is projected to reach USD 31.60 billion by 2034, expanding at a CAGR of 8.5% over the forecast period. Growth is underpinned by the rising prevalence of prostate cancer, expanding adoption of precision diagnostics, and accelerating development of targeted therapies across key end-use industries.

What Is Driving Prostate Cancer Treatment Market Growth?

Demand is climbing as the rising global prevalence of prostate cancer converges with advances in diagnostic and therapeutic technologies. Manufacturers and healthcare providers are prioritizing biomarker-driven, personalized treatment selection, pushing adoption of hormonal therapies, targeted therapies, and radiopharmaceuticals across hospital and specialty care settings. Polaris analysts note that growing awareness and screening programs position the segment for steady growth through 2034, with hormonal therapy emerging as the largest revenue contributor and targeted therapy posting the fastest incremental gains.

Key Trends Shaping the Prostate Cancer Treatment Industry

Shift Toward Personalized and Precision Medicine

Increasing focus on precision medicine is driving treatments tailored to individual genetic profiles and biomarkers, with radiopharmaceuticals and PARP inhibitors expanding therapeutic options for patients with specific genetic mutations.

Advancements in Imaging and Diagnostics

Enhanced imaging techniques such as multiparametric MRI and PSMA PET-CT are improving early detection and staging accuracy, supporting more precise treatment planning and better patient outcomes.

Growing Adoption of AI-Guided Treatment Decisions

AI-driven platforms are increasingly used to integrate imaging, biomarkers, and pathology data, helping clinicians reduce unnecessary biopsies and guide risk-based treatment decisions for localized prostate cancer.

Market Segmentation: Breaking Down the Prostate Cancer Treatment Market

Polaris segments the prostate cancer treatment market by drug class, distribution channel, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Drug Class

The hormonal therapy segment held the largest revenue share in 2024, given its widespread use as first-line treatment for advanced and metastatic prostate cancer through androgen deprivation therapies and androgen receptor inhibitors. Targeted therapy is projected to register the highest growth during the forecast period, driven by rising approvals of radiopharmaceuticals and PARP inhibitors for genetically defined patient populations.

By Distribution Channel

Hospital pharmacies dominated the market in 2024, reflecting their central role in administering hormonal, chemotherapy, and targeted therapies under professional supervision. Online pharmacies are experiencing the highest growth rate, driven by increasing digitalization, telemedicine adoption, and patient preference for convenient, home-based access to oral medications.

Regional Outlook: Where Is Prostate Cancer Treatment Growing Fastest?

North America held the largest share of prostate cancer treatment market revenue in 2024, driven by the high prevalence of the disease, advanced healthcare infrastructure, and strong adoption of innovative therapies. Europe represents a significant market, led by Germany, the UK, and France given their advanced healthcare systems and strong cancer research focus. Asia Pacific is emerging as a rapidly growing market, fueled by increasing healthcare investments, rising disease prevalence, and improved access to medical care in China, Japan, and India.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/prostate-cancer-treatment-market 

Competitive Landscape: Leading Prostate Cancer Treatment Companies

Key players profiled in the report include Johnson & Johnson Services, Inc., Astellas Pharma Inc., Bayer AG, and AstraZeneca Plc, who are focusing on expanding oncology portfolios, biomarker-driven drug development, and strategic partnerships to strengthen market position across the hormonal therapy and hospital pharmacy segments outlined above. Recent moves include Artera's July 2025 FDA Breakthrough Device Designation for ArteraAI Prostate, an AI-powered risk-based treatment decision tool, and Johnson & Johnson's August 2024 positive Phase 3 trial data for a new combination therapy in advanced prostate cancer.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the prostate cancer treatment market, this report benchmarks market share, segment-level pricing, and forecast data — by drug class, distribution channel, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking online pharmacy distribution as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Jars Market

Oral Solid Dosage Contract Manufacturing Market

Agricultural Adjuvants Market

Pad-mounted Switchgear Market

Oral Solid Dosage Contract Manufacturing Market

Solar Panels Market

Mechanical Ventilators Market

The Growing Importance of Customer Experience Management Market

U.S. Desiccant Dehumidifier Market